生命科学资讯

New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program

Theravance halves headcount, ends all R&D work after phase 3 rare disease fail

FDA details rationale for rejecting rare disease gene therapy from Regenxbio

Biohaven reduces scope of R&D cutbacks as pipeline progresses

MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit

Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug

AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal

GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels

HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic

Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout

TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio

Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline

BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline

United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock

Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival